Emmaus Life Sciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

LOSS PER SHARE

LOSS PER SHARE

12 Months Ended

Sep. 30, 2018

10. LOSS PER SHARE

Basic earnings (loss) per share is computed by dividing income (loss) available to common stockholders less the current period preferred stock dividend by the weighted average common shares outstanding during the period. Diluted earnings (loss) per share takes into account the potential dilution that could occur if securities or other contracts to issue Common Stock were exercised and converted into Common Stock.

A summary of the net income (loss) and shares used to compute net income (loss) per share for the fiscal years ended September 30, 2018 and 2017 is as follows:

	2018			2017
Net Loss for computation of basic and diluted net loss per share:
Net loss attributable to MYnd Analytics, Inc.	$	(9,598,700	)	$	(7,112,800	)
Preferred stock dividends		(49,200	)		—
	$	(9,647,900	)	$	(7,112,800	)

Basic and Diluted net loss per share:
Basic net loss per share	$	(1.86	)	$	(2.52	)
Basic and Diluted weighted average shares outstanding		5,199,566			2,817,415

Anti-dilutive common equivalent shares not included in the computation of dilutive net loss per share:
Warrants		6,075,874			957,198
Restricted common stock		406,564			4,500
Options		803,937			359,704